Imaging activated immune response following therapeutic vaccination in an orthotopic glioma model with 89Zr-DFO-OX40 mAb PET
2 Objectives: Glioblastoma (GBM) is one of the most difficult malignancies to eradicate.
Recently, vaccines targeting GBM have shown potential clinical promises (1, 2). In the tumor …
Recently, vaccines targeting GBM have shown potential clinical promises (1, 2). In the tumor …
Whole-body PET imaging of T-cell response to glioblastoma
Purpose: Immunotherapy is a promising approach for many oncological malignancies,
including glioblastoma, however, there are currently no available tools or biomarkers to …
including glioblastoma, however, there are currently no available tools or biomarkers to …
SPECT and PET imaging of CD11b-positive immune cells in an orthotopic mouse model of glioma with Zr-89 and Lu-177 labeled Lumi804-anti-CD11b antibody
S Nigam, D Tatum, A Foster, E Plakseychuk, R Edinger… - 2020 - Soc Nuclear Med
621 Objectives: We recently reported on PET imaging of tumor associated myeloid cells
(TAMCs) with 89 Zr-labeled anti-CD11b antibody in the orthotopic GL261 mouse model of …
(TAMCs) with 89 Zr-labeled anti-CD11b antibody in the orthotopic GL261 mouse model of …
Immuno-PET imaging of activation markers on antigen-specific CD4 T cells in a mouse model of melanoma
609 Objectives: The adoptive transfer of tumor-targeting T cells offers a promising approach
to treating tumors; however, clinical success has been limited. Activation and proliferation …
to treating tumors; however, clinical success has been limited. Activation and proliferation …
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF–expressing tumor cells
Background Glioma immunotherapy is an active area of clinical investigation. Glioma-
associated immunosuppression remains an obstacle to efficacious immunotherapy, and …
associated immunosuppression remains an obstacle to efficacious immunotherapy, and …
[HTML][HTML] Imaging activated T cells predicts response to cancer vaccines
In situ cancer vaccines are under active clinical investigation, given their reported ability to
eradicate both local and disseminated malignancies. Intratumoral vaccine administration is …
eradicate both local and disseminated malignancies. Intratumoral vaccine administration is …
[HTML][HTML] The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic Glioblastoma
L Gold, E Barci, M Brendel, M Orth, J Cheng… - Biomedicines, 2024 - mdpi.com
Background: The translocator protein (TSPO) has been proven to have great potential as a
target for the positron emission tomography (PET) imaging of glioblastoma. However, there …
target for the positron emission tomography (PET) imaging of glioblastoma. However, there …
Preclinical immunoPET imaging of glioblastoma-infiltrating myeloid cells using zirconium-89 labeled anti-CD11b antibody
S Nigam, L McCarl, R Kumar, RS Edinger… - Molecular imaging and …, 2020 - Springer
Purpose Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid
cells (TAMCs). TAMCs are emerging as a promising therapeutic target as they suppress anti …
cells (TAMCs). TAMCs are emerging as a promising therapeutic target as they suppress anti …
Synergy of vaccination and agonist OX40 treatment—toward a mechanism-driven combination of glioma immunotherapy
K Deumelandt, M Platten, K Ochs - Neuro-oncology, 2018 - academic.oup.com
Immunotherapies represent a promising treatment option for different types of cancer, as
evidenced by the increasing number of approved immunotherapeutic drugs. Despite …
evidenced by the increasing number of approved immunotherapeutic drugs. Despite …
[HTML][HTML] Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma …
BB Kasten, HA Houson, JM Coleman… - Scientific Reports, 2021 - nature.com
Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is
a process which can take months. Detection of CD8+ T cell recruitment to the tumor with a …
a process which can take months. Detection of CD8+ T cell recruitment to the tumor with a …